![OX40 [Biotinylated] : OX40 Ligand Inhibitor Screening ELISA Kit](/_ipx/q_100,fit_outside,s_360x255/images/no-image-product-box.jpg "OX40 [Biotinylated] : OX40 Ligand Inhibitor Screening ELISA Kit")
![OX40 [Biotinylated] : OX40 Ligand Inhibitor Screening ELISA Kit](/_ipx/_/images/no-image-product-box.jpg "OX40 [Biotinylated] : OX40 Ligand Inhibitor Screening ELISA Kit")
OX40 [Biotinylated] : OX40 Ligand Inhibitor Screening ELISA Kit
1074.92 €
In Stock
quantity
product details
Catalog number: 716 - EP-162
Product Category: Business & Industrial > Science & Laboratory
Gentaur
Size: 96tests
![OX40 [Biotinylated] : OX40 Ligand Inhibitor Screening ELISA Kit](/images/no-image-product-box.jpg "OX40 [Biotinylated] : OX40 Ligand Inhibitor Screening ELISA Kit")
EP-162
OX40 [Biotinylated] : OX40 Ligand Inhibitor Screening ELISA Kit
Tumor necrosis factor receptor superfamily member 4 (TNFRSF4) is also known as ACT35 antigen, OX40L receptor, TAX transcriptionally-activated glycoprotein 1 receptor, CD antigen CD134, OX40. OX40 / TNFRSF4 contains four TNFR-Cys repeats. TNFRSF4 is receptor for TNFSF4 / OX40L / GP34 and can interacts with TRAF2, TRAF3 and TRAF5.
1074.92 €
EP-162-96tests
OX40 [Biotinylated] : OX40 Ligand Inhibitor Screening ELISA Kit
Tumor necrosis factor receptor superfamily member 4 (TNFRSF4) is also known as ACT35 antigen, OX40L receptor, TAX transcriptionally-activated glycoprotein 1 receptor, CD antigen CD134, OX40. OX40 / TNFRSF4 contains four TNFR-Cys repeats. TNFRSF4 is receptor for TNFSF4 / OX40L / GP34 and can interacts with TRAF2, TRAF3 and TRAF5.
1074.92 €
72045
OX40[Biotinylated]:OX40L Inhibitor Screening Assay Kit
The OX40[Biotinylated]:OX40L Inhibitor Screening Assay Kit is designed for_x000D_screening and profiling inhibitors of OX40:OX40L interaction. The key to this kit is the high sensitivity of detection of biotinlabeled_x000D_OX40 by streptavidin-HRP. Only a few simple steps on a microtiter plate are required for_x000D_the assay. First, OX40L is coated on a 96-well plate. Next, OX40-biotin is incubated with OX40L_x000D_on the plate. Finally, the plate is treated with streptavidin-HRP followed by addition of an HRP_x000D_substrate to produce chemiluminescence, which can then be measured using a_x000D_chemiluminescence reader.
1772.55 €
EP-116
B7-1 [Biotinylated] : CTLA-4 Inhibitor Screening ELISA Kit
Cytotoxic T lymphocyte associated ANTIgen-4 (CTLA-4), also known as CD152, is a kind of leukocyte differentiation antigen and a transmembrane receptor on T cells, sharing B7 ligand with CD28. The binding of CTLA-4 with B7 induces T cells to be non-reactive and participates in the negative regulation of immune response. The recombinant CTLA-4 Ig can effectively and specifically inhibit cellular and humoral immune responses in vivo and in vitro, and has significant therapeutic effects on transplant rejection and various autoimmune diseases with very low toxicity. It is considered as a promising new immunosuppressive drug at present.
1074.92 €
EP-116-96tests
B7-1 [Biotinylated] : CTLA-4 Inhibitor Screening ELISA Kit
Cytotoxic T lymphocyte associated ANTIgen-4 (CTLA-4), also known as CD152, is a kind of leukocyte differentiation antigen and a transmembrane receptor on T cells, sharing B7 ligand with CD28. The binding of CTLA-4 with B7 induces T cells to be non-reactive and participates in the negative regulation of immune response. The recombinant CTLA-4 Ig can effectively and specifically inhibit cellular and humoral immune responses in vivo and in vitro, and has significant therapeutic effects on transplant rejection and various autoimmune diseases with very low toxicity. It is considered as a promising new immunosuppressive drug at present.
1074.92 €
EP-117
B7-2 [Biotinylated] : CTLA-4 Inhibitor Screening ELISA Kit
Cytotoxic T lymphocyte associated ANTIgen-4 (CTLA-4), also known as CD152, is a kind of leukocyte differentiation antigen and a transmembrane receptor on T cells, sharing B7 ligand with CD28. The binding of CTLA-4 with B7 induces T cells to be non-reactive and participates in the negative regulation of immune response. The recombinant CTLA-4 Ig can effectively and specifically inhibit cellular and humoral immune responses in vivo and in vitro, and has significant therapeutic effects on transplant rejection and various autoimmune diseases with very low toxicity. It is considered as a promising new immunosuppressive drug at present.